We explored the relative merits of employing CD25-biased versus CD25-blocking anti-IL-2 antibodies, revealing the unexpected therapeutic advantage for CD25-biased anti-IL-2 antibodies in the context of ICI combination therapy for cancer treatment. Here, IL2 is linked to cancer.